Stent revascularization versus bypass surgery for peripheral artery disease in type 2 diabetic patients – an instrumental variable analysis

Chia-Hsuin Chang1,2,3, Jou-Wei Lin1,2,4, Jiun Hsu4,5, Li-Chiu Wu3 & Mei-Shu Lai3

The objective of this study was to use instrumental variable (IV) analyses to evaluate the clinical effectiveness of percutaneous stent revascularization versus bypass surgery in the treatment of peripheral artery disease (PAD) among type 2 diabetic patients. Type 2 diabetic patients who received peripheral artery bypass surgery (n = 5,652) or stent revascularization (n = 659) for lower extremity arterial stenosis between 2000 and 2007 were identified from the Taiwan National Health Insurance claims database. Patients were followed from the date of index hospitalization for 2 years for lower-extremity amputation, revascularization, and hospitalization for medical treatment. Analysis using treatment year, patients’ monthly income level, and regional difference as IVs were conducted to reduce unobserved treatment selection bias. The crude analysis showed a statistically significant risk reduction in favor of stent placement in lower extremity amputation and in the composite endpoint of amputation, revascularization, or hospitalization for medical treatment. However, peripheral artery stent revascularization and bypass surgery had similar risk of lower limb amputation and composite endpoints in the analyses using calendar year or patients’ monthly income level as IVs. These two treatment modalities had similar risk of lower limb amputation among DM patients with PAD.

Peripheral artery disease (PAD), which results from progressive narrowing of arteries secondary to atherosclerosis, has increased in prevalence and put a severe burden on the patients as well as the economy1,2. Patients with type 2 diabetes mellitus (DM) are at increased risk of developing lower extremity PAD3,4. Diabetic patients with PAD commonly show involvement of the arteries below the knee, especially at the tibial and peroneal arteries, and involvement of the profunda femoris5. Although diabetic patients with PAD have similar primary patency rates, restenosis, and secondary patency rates compared to non-diabetic patients, the mortality and amputation rates are markedly higher in DM patients6,7.

Endovascular revascularization and open bypass surgery are the two strategies for managing PAD patients with disabling claudication after medical therapy has failed to improve symptoms and those with critical limb ischemia8,9. The choice of a procedure depends on many factors, such as site and extent of the disease, distal runoff and surgical risk due to associated cardiovascular disease6,10. Proximal, short segment disease in the iliac and femoral segments is amenable to percutaneous transluminal angioplasty (PTA). Studies suggested that for the treatment of focal iliac stenosis and occlusion, PTA with or without stenting has become a viable alternative to surgical reconstruction due to its safety and acceptable long-term outcomes11–13. Recent guidelines even suggest an “endovascular first” approach when revascularization is indicated14.

Controversies exist as which one is the better treatment modality for more distal disease in the popliteal and tibial arteries15,16. Patients with more advanced and extensive occlusive disease is better managed by bypass grafting; however, the procedure is hindered by complications that result in severe morbidity and excessive costs. PTA below the knee is recommended to patients with critical limb ischemia who are at high risk during
surgical revascularization because of comorbidities. It may achieve satisfactory limb salvages rates at least in the short-term. However, regarding the distal and diffuse nature of the disease in diabetic patients, PTA are technically difficult to perform. In particular, little is known regarding the comparative effectiveness of stent revascularization versus bypass surgery, and currently available literature suggests that there is probably no difference in the clinical outcome. To our knowledge, no randomized trial comparing the efficacy between endovascular stenting and bypass surgery in diabetic patients with lower extremity PAD has been published. Despite an increasing number of DM patients received stent revascularization for lower extremity arterial occlusive disease, a large-scale study comparing the clinical effectiveness in limb salvage between those who underwent percutaneous stent revascularization or bypass surgery for more distal lower extremity arterial disease in real clinical setting is still lacking. Because patients were selected for treatment modality primarily based on the anatomy and extent of the disease, and the detailed information on vascular anatomy was not available in most databases, traditional multivariable regression analysis controlling for only measured and recorded variables may not provide valid results. Compared with standard modeling, instrumental variable (IV) analysis may produce less biased estimates of treatment effect in the setting that unmeasured patients characteristics affect both the decision to treat the the outcome. In this study, we conducted IV analyses to reduce potential treatment selection bias and to compare the results from analyses using different IVs.

Results
A total of 6,342 new patients receiving endovascular stents or bypass surgery for lower extremity arterial stenosis were identified during the study period. After exclusion of patients receiving both bypass surgery and stents in the same treatment episode, a total of 659 and 5,652 type 2 diabetic patients received peripheral artery stents and bypass surgery, respectively (Fig. 1). As identified in Table 1, the two treatment groups differed in a number of baseline characteristics. Patients receiving stenting were older, with higher proportion of male, more likely to have ischemic heart and cerebrovascular disease, and receiving oral diabetic agents, aspirin, clopidogrel, cilostazol, statins, and prior history of coronary revascularization. In contrast, patients receiving bypass surgery were
|                       | Original cohort |          |          | P values |
|-----------------------|----------------|----------|----------|----------|
| **Age (mean ± SD)**   |                 | Bypass surgery (N = 5,652) | Stenting (N = 659) |          |
|                       |                 | 67.96 ± 10.12 | 71.20 ± 8.68 | <0.001   |
| **Male (%)**          |                 | 48.53     | 66.46    | <0.001   |
| **Calendar year (%)** |                 | 39.97     | 0.00     | <0.001   |
| 2000–2002             |                 | 36.13     | 39.91    |          |
| 2006–2007             |                 | 23.90     | 60.09    |          |
| **Monthly income in New Taiwan Dollar (%)** |           | 58.10     | 68.13    | <0.001   |
| ≤17,280               |                 | 34.52     | 23.37    |          |
| 17,281–22,800         |                 | 2.34      | 2.28     |          |
| 22,801–28,800         |                 | 1.86      | 2.73     |          |
| 28,801–36,300         |                 | 1.70      | 1.52     |          |
| 36,301–45,800         |                 | 1.49      | 1.97     |          |
| **Region (%)**        |                 | 42.52     | 61.76    | <0.001   |
| Northern              |                 | 22.08     | 17.15    |          |
| Southern              |                 | 35.40     | 21.09    |          |
| **Hospitalization department (%)** |            | 4.14      | 52.96    | <0.001   |
| Cardiologist          |                 | 45.68     | 37.03    |          |
| Other                 |                 | 50.18     | 10.02    |          |
| **Comorbidities (%)** |                 |           |          |          |
| Cardiovascular disease|                 | 90.15     | 97.42    | <0.001   |
| Ischemic heart disease|                 | 45.24     | 64.19    | <0.001   |
| Cerebrovascular disease|               | 28.95     | 55.69    | <0.001   |
| Ketoacidosis or hyperosmolarity |           | 3.79      | 1.97     | 0.018    |
| Retinopathy           |                 | 30.52     | 29.29    | 0.515    |
| Neuropathy            |                 | 34.34     | 28.53    | 0.003    |
| Nephropathy           |                 | 73.66     | 50.08    | <0.001   |
| Myocardial infarction |                 | 6.51      | 7.44     | 0.366    |
| Ischemic stroke       |                 | 17.85     | 46.74    | <0.001   |
| Chronic renal failure |                 | 53.47     | 22.15    | <0.001   |
| Chronic liver disease |                 | 11.31     | 10.47    | 0.520    |
| Chronic lung disease  |                 | 22.52     | 22.46    | 0.970    |
| Depression            |                 | 5.68      | 5.77     | 0.927    |
| Charlson’s index (mean ± SD) |           | 4.88 ± 2.36 | 4.09 ± 2.26 | <0.001 |
| Number of different ICD-9 diagnoses (mean ± SD) |     | 21.68 ± 9.78 | 21.34 ± 9.80 | 0.402 |
| Number of cardiovascular-related diagnoses (mean ± SD) | | 3.50 ± 2.81 | 4.78 ± 3.12 | <0.001 |
| **Medication use (%)**|                 |           |          |          |
| Biguanides            |                 | 44.37     | 62.97    | <0.001   |
| Sulfonylurea          |                 | 61.92     | 72.53    | <0.001   |
| Alpha glucosidase inhibitors |         | 11.48     | 19.73    | <0.001   |
| Thiazolidinediones    |                 | 11.91     | 20.94    | <0.001   |
| Glinides              |                 | 15.99     | 18.06    | 0.174    |
| Any oral anti-diabetic agents |       | 72.08     | 83.46    | <0.001   |
| Fast-acting insulins  |                 | 49.91     | 32.32    | <0.001   |
| Basal insulins        |                 | 16.54     | 11.53    | 0.001    |
| Aspirin               |                 | 64.23     | 78.15    | <0.001   |
| Clopidogrel           |                 | 12.85     | 44.76    | <0.001   |
| Cilastazol            |                 | 15.34     | 23.07    | <0.001   |
| Warfarin              |                 | 7.02      | 7.28     | 0.805    |
| ACE inhibitors        |                 | 45.67     | 42.03    | 0.076    |
| Angiotensin receptor blockers |       | 34.68     | 52.20    | <0.001   |
| Alpha-blockers        |                 | 17.37     | 22.61    | <0.001   |
| Beta-blockers         |                 | 50.50     | 62.37    | <0.001   |

Continued
The odds ratio between instruments and endovascular stenting as the measurement of strength of association was 4.79 for calendar year 2006–2007 (Table 2), 1.54 for monthly income level \( \leq \) 17,280 NTD (Table 3), and 2.18 for the hospital located in northern Taiwan as a measure of regional difference (Table 4). The baseline data and mean predicted probability of lower limb amputation between the early (2003–2005) and late (2006–2007) treatment groups were shown in Table 2. Baseline demographics, co-morbidities, medication use, resource utilization, and amputation rates were similar between two groups, although a higher proportion of patients in the early treatment group received biguanides, sulfonylurea, clopidogrel, and underwent amputation at the index hospitalization. Despite of these small differences, the variables assumed as proxies of arterial stenosis severity (the proportion of those with prior amputation, the mean number of cardiovascular surgeon outpatient visits, and the mean number of hospitalizations due to lower extremity complications) were similar between the early and late periods. Meanwhile, the predicted probability of lower extremity amputation after initial management, our outcome of interest, was also similar between two groups (Table 2). Meanwhile, although peripheral artery stent recipients with monthly income level \( \leq \) 17,280 NTD were older and more likely to have cardiovascular and cerebrovascular diseases but less likely to have chronic renal disease as compared with those with monthly income level > 17,280 NTD, the mean predicted probability of amputation was similar between two groups (Table 3). These findings support the use of calendar year and perhaps patients’ monthly income level as a valid instrumental variable. In contrast, patients receiving peripheral artery stenting at non-northern hospitals had positive association with some risk factors of the outcome, for example, neuropathy and chronic renal disease, and had a significantly higher probability of lower limb amputation, raising the concerns that the regional difference as measured by the hospital location might also be associated with other unmeasured confounders (Table 4).

| Resource utilization (mean ± SD) | Bypass surgery (N = 5,652) | Stenting (N = 659) | P values |
|----------------------------------|-----------------------------|-------------------|---------|
| Number of A1C measurement        | 1.34 ± 1.61                 | 2.07 ± 1.88       | <0.001  |
| Number of lipid-related lab test | 4.35 ± 5.05                 | 5.64 ± 5.04       | <0.001  |
| Number of peripheral artery ultrasound examination | 0.03 ± 0.23 | 0.03 ± 0.21 | 0.039 |
| Number of outpatient visits due to diabetes | 15.76 ± 11.25 | 18.08 ± 12.09 | <0.001 |
| Number of outpatient visits not due to diabetes | 46.06 ± 24.97 | 50.65 ± 28.98 | <0.001 |
| Number of emergency department visit | 1.94 ± 2.73 | 1.48 ± 2.56 | <0.001 |
| Number of cardiology outpatient visits | 7.12 ± 10.19 | 5.70 ± 8.87 | <0.001 |
| Number of cardiovascular surgery outpatient visits | 3.55 ± 6.55 | 2.42 ± 5.11 | <0.001 |
| Number of cardiovascular-related physician visits | 13.18 ± 11.02 | 19.51 ± 12.36 | <0.001 |
| Coronary revascularization % &lt; 3.18 &lt; 10.93 &lt; 0.001 &lt; 11.23 &lt; 4.10 &lt; 0.001 &lt; 17.00 &lt; 2.43 &lt; 0.001 &lt; 1.68 ± 1.81 &lt; 1.00 ± 1.38 &lt; 0.001 &lt; 2.09 ± 2.14 &lt; 1.27 ± 1.59 &lt; 0.001 &lt; 0.42 ± 0.85 &lt; 0.13 ± 0.44 &lt; 0.001 &lt; 23.29 ± 34.96 &lt; 11.62 ± 24.22 &lt; 0.001 &lt; 1.32 ± 1.66 &lt; 1.07 ± 1.40 &lt; 0.001 &lt; 15.61 &lt; 1.66 &lt; 0.001 &lt; 26.82 &lt; 1.76 &lt; 0.001 &lt; 2.51 &lt; 1.06 &lt; 0.020 &lt; 11.71 &lt; 5.92 &lt; 0.001 &lt; 18.88 &lt; 8.50 &lt; 0.001

Table 1. Baseline characteristics of type 2 diabetic patients with lower extremity artery stenosis during the 12-month period preceding peripheral artery bypass surgery or stenting. SD: standard deviation.

more likely to have retinopathy, nephropathy, and chronic renal disease, and insulin therapy. Higher proportion of the patients had prior history of lower extremity amputation, hospitalization for diabetes, and lower extremity complications.
|                          | 2003–2005 (N = 263) | 2006–2007 (N = 396) | P-value |
|--------------------------|---------------------|---------------------|---------|
| Age (mean ± SD)          | 70.44 ± 8.34        | 71.71 ± 8.88        | 0.066   |
| Male (%)                 | 67.68               | 65.66               | 0.590   |
| Comorbidities            |                     |                     |         |
| Diabetes-related late complications (%) |                     |                     |         |
| Cardiovascular disease   | 98.48               | 96.72               | 0.162   |
| Ischemic heart disease   | 64.64               | 63.89               | 0.844   |
| Cerebrovascular disease  | 61.22               | 52.02               | 0.020   |
| Ketoacidosis or hyperosmolarity | 2.28 | 1.77               | 0.642   |
| Retinopathy              | 30.42               | 28.54               | 0.603   |
| Neuropathy               | 27.76               | 29.04               | 0.721   |
| Nephropathy              | 46.77               | 52.27               | 0.166   |
| Myocardial infarction    | 8.75                | 6.57                | 0.296   |
| Ischemic stroke          | 51.33               | 43.69               | 0.054   |
| Chronic renal failure    | 18.63               | 24.49               | 0.076   |
| Chronic liver disease    | 11.41               | 9.85                | 0.522   |
| Chronic lung disease     | 26.62               | 19.70               | 0.037   |
| Depression               | 5.32                | 6.06                | 0.691   |
| Charlson’s index (mean ± SD) | 4.10 ± 2.34        | 4.09 ± 2.21         | 0.982   |
| Number of different ICD-9 diagnoses (mean ± SD) | 21.46 ± 10.16       | 21.26 ± 9.57        | 0.800   |
| Number of cardiovascular-related diagnoses (mean ± SD) | 5.11 ± 3.10         | 4.56 ± 3.13         | 0.027   |
| Medication use (%)       |                     |                     |         |
| Biguanides               | 69.96               | 58.33               | 0.002   |
| Sulfonylurea             | 77.95               | 68.94               | 0.011   |
| Alpha-glucosidase inhibitors | 16.73            | 21.72               | 0.115   |
| Thiazolidinediones       | 22.05               | 20.20               | 0.567   |
| Glinides                 | 19.77               | 16.92               | 0.351   |
| Fast-acting insulins     | 31.18               | 33.08               | 0.609   |
| Basal insulins           | 12.93               | 10.61               | 0.361   |
| Aspirin                  | 80.61               | 76.52               | 0.213   |
| Clopidogrel              | 50.19               | 41.16               | 0.022   |
| Cilostazol               | 19.39               | 25.51               | 0.068   |
| Warfarin                 | 9.13                | 6.06                | 0.138   |
| ACE inhibitors           | 43.73               | 40.91               | 0.473   |
| Angiotensin receptor blockers | 56.65            | 49.24               | 0.062   |
| Alpha-blockers           | 24.33               | 21.46               | 0.388   |
| Beta-blockers            | 64.26               | 61.11               | 0.414   |
| Calcium channel blockers | 78.71               | 75.00               | 0.272   |
| Directics                | 59.70               | 53.54               | 0.119   |
| Statins                  | 52.85               | 52.27               | 0.884   |
| Fibrates                 | 14.45               | 15.91               | 0.610   |
| Resource utilization (mean ± SD) |                     |                     |         |
| Number of A1C measurement | 2.00 ± 1.87        | 2.11 ± 1.89         | 0.448   |
| Number of lipid-related lab test | 5.75 ± 5.35      | 5.57 ± 4.83         | 0.657   |
| Number of peripheral artery ultrasound examination | 0.02 ± 0.12        | 0.04 ± 0.25         | 0.058   |
| Number of outpatient visits due to diabetes | 19.04 ± 12.26      | 17.45 ± 11.95       | 0.099   |
| Number of outpatient visits not due to diabetes | 50.90 ± 31.05      | 50.49 ± 27.56       | 0.863   |
| Number of emergency department visit | 1.33 ± 2.22      | 1.58 ± 2.76         | 0.195   |
| Number of cardiology outpatient visits | 5.69 ± 9.13       | 5.70 ± 8.70         | 0.982   |
| Number of cardiovascular surgeon outpatient visits | 2.87 ± 6.29       | 2.13 ± 4.14         | 0.091   |
| Number of cardiovascular-related physician visits | 20.08 ± 11.96     | 19.13 ± 12.63       | 0.335   |
| Coronary revascularization % | 9.89              | 11.62               | 0.486   |
| Prior amputation %       | 3.04                | 4.80                | 0.265   |
| Amputation at index hospitalization % | *               | *                   | 0.223   |
| Number of hospitalization due to diabetes | 1.08 ± 1.49      | 0.94 ± 1.29         | 0.244   |
| Number of hospitalization not due to diabetes | 1.33 ± 1.65      | 1.23 ± 1.55         | 0.438   |
| Number of hospitalization due to lower extremity complications | 0.15 ± 0.50      | 0.12 ± 0.39         | 0.400   |

Continued
patients’ surgical risks, symptoms, detailed vascular anatomy, presence and severity of underlying diseases, revascularization. In order to make a valid comparison between treatment groups, important information such as using non-experimental design to examine comparative effectiveness and safety between open surgery and stent device safety and effectiveness in the real-world settings. However, substantial challenges exit particularly while consistent with the conclusion from the BASIL trial. Our study findings suggested that instrumental variable analysis which assumed to provide valid estimates even without measuring the confounders were founding still persisted by using conventional multivariable regression approach. Therefore, research methodology comprehensive registry data, these variables were incompletely measured and recorded such that residual con- comitant medications, and lifestyle factors were needed to be collected and taken into consideration. Even in the deviation.

Table 2. Baseline characteristics and clinical outcomes of diabetic patients with lower extremity arterial stenosis receiving peripheral artery stenting by calendar year. *Any one of the cells < 3 SD: standard deviation.

| Outcome occurrence (%) | 2003–2005 (N = 263) | 2006–2007 (N = 396) | P-value |
|-------------------------|----------------------|---------------------|---------|
| Mean predicted probability of lower limb amputation | 0.06 ± 0.14 | 0.08 ± 0.16 | 0.095 |
| Amputation, revascularization, or hospitalization for medical treatment | 6.84 | 9.60 | 0.215 |
| Foot, ankle, leg | 4.94 | 6.57 | 0.387 |
| Thigh | 1.14 | 1.01 | 0.999 |
| Amputation | 6.08 | 8.08 | 0.334 |
| Number of hospital days | 11.67 ± 20.75 | 11.59 ± 26.30 | 0.967 |
| Number of cardiovascular-related hospital days | 1.11 ± 1.42 | 1.04 ± 1.38 | 0.552 |

The crude analysis showed a statistically significant risk reduction in favor of stent placement in lower extremity amputation and in the composite endpoint of amputation, revascularization, or hospitalization for medical treatment (Table 5). However, peripheral artery stent revascularization and bypass surgery had similar risk of lower limb amputation and composite endpoints in the analyses using calendar year as patients’ monthly income level as IV. Risk difference between two treatment modalities was −0.003 (95% CI: −0.053–0.046; p = 0.89) for lower limb amputation and −0.027 (95% CI: −0.080–0.026; p = 0.31) for the composite endpoint of amputation, revas- cularization, or hospitalization for medical treatment while using calendar year as IV; and the risk difference was 0.058 (95% CI: −0.055–0.171; p = 0.31) and 0.016 (95% CI: −0.105–0.137; p = 0.79) for the two outcomes, respectively, in the analysis using monthly income level as IV (Table 5). In contrast, stent revascularization was associated with a significantly higher risk of amputation and composite endpoint in the analysis using regional difference as IV. This set of estimators were biased as regional difference did not perfectly meet the instrumental conditions (see above).

Discussion
The results of this study demonstrated that, among type 2 diabetic patients, percutaneous stent revascularization for lower extremity arterial stenosis is not superior to open bypass surgery in reducing lower limb amputation rates during the first two years following the procedure. The stent-based endovascular procedure was also found to result in a similar risk of the composite endpoint consisting of amputation, revascularization, or hospitalization for medical treatment.

Rapidly evolving technology in stent procedure causes tremendous changes in clinical practice that occur so quickly even before the randomized controlled trials can be completed. The most current guidelines regarding the revascularization treatment of lower extremity PAD continue to be based upon the implications from the randomized BASIL (Bypass Versus Angioplasty in Severe Ischemia of the Leg) trial published several years ago, which suggests similar amputation-free survival with a bypass-surgery-first and a balloon-angioplasty-first strategy in patients with severe limb ischemia due to infra-inguinal disease. Constrained by the insufficient evidence due to limited data, further studies to confirm or refute these findings and recommendations are urgently required as there was a substantial increase in the number of patients receiving lower extremity percutaneous stent revascularization during the past decade. Analyzing observational data may provide a timely evaluation for medical device safety and effectiveness in the real-world settings. However, substantial challenges exit particularly while using non-experimental design to examine comparative effectiveness and safety between open surgery and stent revascularization. In order to make a valid comparison between treatment groups, important information such as patients’ surgical risks, symptoms, detailed vascular anatomy, presence and severity of underlying diseases, concomitant medications, and lifestyle factors were needed to be collected and taken into consideration. Even in the comprehensive registry data, these variables were incompletely measured and recorded such that residual confounding still persisted by using conventional multivariable regression approach. Therefore, research methodology that can handle unmeasured confounding is particularly useful in this setting. Our study results from an instrumental variable analysis which assumed to provide valid estimates even without measuring the confounders were consistent with the conclusion from the BASIL trial. Our study findings suggested that instrumental variable analysis might effectively reduce confounding by indication, which was a more serious problem in the setting of non-pharmacological therapy as compared with pharmacological treatment.

In the present study, we conducted analyses utilizing several potential instruments. Although treatment calendar year and patients’ income level might conceptually meet the required assumptions, it was more appropriate to use calendar year as the instrument based on empirical data because it had a higher strength of association with treatment and there was evidence that it was not associated with measured confounders nor the outcome. Results from analysis using patients’ monthly income level as the instrument did not substantially change conclusion, although monthly income level had a lower association with treatment and there was some association with certain measured proxy for the severity of lower-extremity vascular occlusion. It was surprisingly shown that patients’ characteristics and perhaps disease severity varied among different regions. Meanwhile, it is possible that the regional difference in operators’ experiences can directly influence patients’ outcome. Our study findings
|                         | Monthly income ≤ 17,280 (N = 449) | Monthly income > 17,280 (N = 210) | P-value |
|------------------------|-----------------------------------|-----------------------------------|---------|
| **Age (mean ± SD)**    | 72.69 ± 8.04                     | 68.01 ± 9.16                     | <0.001  |
| **Male (%)**           | 68.37                             | 62.38                             | 0.129   |
| **Comorbidities**      |                                   |                                   |         |
| **Diabetes-related late complications (%)** |                                   |                                   |         |
| Cardiovascular disease | 98.44                             | 95.24                             | 0.016   |
| Ischemic heart disease | 65.48                             | 61.43                             | 0.312   |
| Cerebrovascular disease| 58.80                             | 49.05                             | 0.019   |
| Ketoacidosis or hyperosmolarity | 2.00                             | 1.90                             | 1.000   |
| Retinopathy            | 32.29                             | 22.86                             | 0.013   |
| Neuropathy             | 28.73                             | 28.10                             | 0.866   |
| Nephropathy            | 47.66                             | 55.24                             | 0.070   |
| Myocardial infarction  | 6.68                              | 9.05                              | 0.281   |
| Ischemic stroke        | 48.33                             | 43.33                             | 0.231   |
| Chronic renal failure  | 19.60                             | 27.62                             | 0.021   |
| Chronic liver disease  | 9.58                              | 12.38                             | 0.273   |
| Chronic lung disease   | 22.94                             | 21.43                             | 0.665   |
| Depression             | 7.13                              | 2.86                              | 0.028   |
| Charlson’s index (mean ± SD) | 4.05 ± 2.22                    | 4.19 ± 2.36                       | 0.470   |
| Number of different ICD-9 diagnoses (mean ± SD) | 21.72 ± 9.88                   | 20.53 ± 9.61                      | 0.146   |
| Number of cardiovascular-related diagnoses (mean ± SD) | 4.78 ± 3.00                     | 4.76 ± 3.38                       | 0.936   |
| **Medication use (%)** |                                   |                                   |         |
| Biguanides             | 64.59                             | 59.52                             | 0.210   |
| Sulfonylurea           | 71.27                             | 75.24                             | 0.288   |
| Alpha-glucosidase inhibitors | 19.15                          | 20.95                             | 0.589   |
| Thiazolidinediones     | 22.27                             | 18.10                             | 0.220   |
| Glinides               | 16.93                             | 20.48                             | 0.270   |
| Fast-acting insulins   | 32.74                             | 31.43                             | 0.737   |
| Basal insulins         | 11.36                             | 11.90                             | 0.838   |
| Aspirin                | 79.06                             | 76.19                             | 0.405   |
| Clopidogrel            | 43.65                             | 47.14                             | 0.401   |
| Cilostazol             | 24.28                             | 20.48                             | 0.281   |
| Warfarin               | 6.24                              | 9.52                              | 0.130   |
| ACE inhibitors         | 41.87                             | 42.38                             | 0.902   |
| Angiotensin receptor blockers | 54.79                          | 46.67                             | 0.052   |
| Alpha-blockers         | 25.17                             | 17.14                             | 0.022   |
| Beta-blockers          | 63.03                             | 60.95                             | 0.608   |
| Calcium channel blockers | 77.28                          | 74.76                             | 0.477   |
| Diuretics              | 56.12                             | 55.71                             | 0.921   |
| Statins                | 52.34                             | 52.86                             | 0.901   |
| Fibrates               | 14.25                             | 17.62                             | 0.264   |
| **Resource utilization (mean ± SD)** |                                   |                                   |         |
| Number of A1C measurement | 2.17 ± 1.91                   | 1.84 ± 1.80                       | 0.035   |
| Number of lipid-related lab test | 5.87 ± 5.07                    | 5.15 ± 4.95                       | 0.085   |
| Number of peripheral artery ultrasound examination | 0.03 ± 0.19                    | 0.03 ± 0.24                       | 0.797   |
| Number of outpatient visits due to diabetes | 19.24 ± 12.89                 | 15.61 ± 9.75                      | <0.001  |
| Number of outpatient visits not due to diabetes | 52.66 ± 29.75                 | 46.36 ± 26.84                     | 0.009   |
| Number of emergency department visit | 1.66 ± 2.91                     | 1.10 ± 1.47                       | 0.001   |
| Number of cardiology outpatient visits | 5.94 ± 9.18                    | 5.19 ± 8.15                       | 0.311   |
| Number of cardiovascular surgeon outpatient visits | 2.47 ± 5.09                    | 2.31 ± 5.18                       | 0.708   |
| Number of cardiovascular-related physician visits | 20.84 ± 13.01                  | 16.68 ± 10.32                     | <0.001  |
| Coronary revascularization % | 10.47                          | 11.90                             | 0.582   |
| Prior amputation %     | 2.45                              | 7.62                              | 0.002   |
| Amputation at index hospitalization % | 2.45                          | 2.38                              | 0.957   |
| Number of hospitalization due to diabetes | 0.97 ± 1.36                    | 1.05 ± 1.41                       | 0.519   |
| Number of hospitalization not due to diabetes | 1.23 ± 1.58                    | 1.37 ± 1.63                       | 0.296   |

Continued
suggested that using an instrumental variable that was associated with unmeasured poor prognostic factors for the outcome might "over-correct" the true association between exposure of interest and outcome. Further simulation studies are required to quantitatively evaluate the direction and magnitude of bias when there was a relation between the instrument and measured confounders.

This study has some limitations that warrant mention. First, the use of data from a national claims database prevented us from distinguishing between inflow revascularization procedures (aortoiliac) and infragenital (femoropopliteal) procedures. Although diabetic patients with PAD commonly had arterial occlusion below the knee, it is still conceivable that stenting could have been performed more commonly than surgery for those with iliac disease, where more favorable outcomes would be expected. In contrast, smoking, obesity, and body height, despite that they were risk factors for lower limb arterial stenosis and amputation, did not confound study results as they were not associated with treatment decision. Second, as endovascular intervention for peripheral artery stenosis was relatively a new medical technology as compared with open bypass surgery during the study period, we could not exclude the possibility that the safety and effectiveness of stent revascularization may improve after operators become more experienced. Third, as the instrumental analysis only provided marginal effect estimates, we did not further explore whether the comparative effectiveness of stenting versus surgery may be different in certain risk groups. Fourth, we excluded the cases who received balloon angioplasty only and who received both stent revascularization and bypass surgery. Accordingly, we remain conservative in generalizing our results to strategies other than the stent-first and surgery-first approach. Finally, since the follow-up duration was only 2.0 years, a longer time is required to observe the long-term effects of different revascularization strategies.

The evaluation of clinical outcomes between stent and surgery for PAD could be biased if the data were obtained from a direct comparison of two "unbalanced" groups in a claims database. The instrumental variable behaves like a natural randomization if it is highly correlated with treatment, but not related to patient characteristics or other confounding factors, nor directly affecting the outcome of interest. 'Treatment calendar year and patients' income level meet the required assumptions of good instrumental variables. In conclusion, this quasi-experimental study showed that percutaneous stent revascularization was associated with a similar risk of lower limb amputation as compared with open bypass surgery for type 2 diabetic patients with PAD. Although these results can inform a potential revision of the recommendations for PAD treatment, further randomized clinical trials are warranted.

Methods

Data Source. Taiwan's National Health Insurance (NHI) database includes complete outpatient visits, hospital admissions, prescriptions, disease and vital status for 99% of the country's population (approximately 23 million) in Taiwan. The claims datasets were linked with the National Death Registry through the use of birth dates and civil identification numbers unique to each beneficiary. The protocol of this study was approved by the National Taiwan University Hospital Research Ethics Committee. Informed consent was waived due to the retrospective and anonymous nature of the claims data. All analyses were performed in accordance with relevant guidelines and regulations.

Diabetic Cohort. All patients' records tagged with a diabetes diagnosis code (Supplementary Table 1) between 1 January 2000 and 31 December 2000 were retrieved from the claims database. An algorithm demonstrated a high level of sensitivity and positive predictive value (93.2% and 92.3%, respectively) for identifying DM patients. A total of 640,173 patients was identified using the algorithm. Patients were followed from the date of DM diagnosis in 2000 until death, disenrollment from the national health insurance, or the end of the study period (31 December 2008).

Study Population and Comparison Groups. Using services or procedure claims documented between 1 January 2000 and 31 December 2007, we identified patients who received peripheral artery bypass surgery or stent placement for lower extremity arterial stenosis. The date of hospitalization was defined as the index date. Four types of percutaneous stents were approved for treating peripheral arterial stenosis in Taiwan during the

| Outcome occurrence (%) | Monthly income ≤ 17,280 (N = 449) | Monthly income > 17,280 (N = 210) | P-value |
|------------------------|-----------------------------------|-----------------------------------|---------|
| Number of hospitalization due to lower extremity complications | 0.14 ± 0.41 | 0.13 ± 0.50 | 0.853 |
| Number of hospital days | 11.28 ± 23.93 | 12.35 ± 24.88 | 0.598 |
| Number of cardiovascular-related hospital days | 1.04 ± 1.39 | 1.11 ± 1.40 | 0.550 |
| Mean predicted probability of lower limb amputation | 0.07 ± 0.15 | 0.08 ± 0.15 | 0.696 |

Table 3. Baseline characteristics and clinical outcomes of diabetic patients with lower extremity arterial stenosis receiving peripheral artery stenting by patients' monthly income level. *Any one of the cell <3. Standardized mean difference using monthly income >17,280 as the reference. SD: standard deviation
### Age and Sex

|                           | Northern (N = 407) | Non-northern (N = 252) | P-value |
|---------------------------|--------------------|------------------------|---------|
| Age (mean ± SD)           | 72.06 ± 8.46       | 69.81 ± 8.87           | 0.001   |
| Male (%)                  | 66.34              | 66.67                  | 0.931   |

### Comorbidities

#### Diabetes-related late complications (%)

| Condition                          | Northern | Non-northern | P-value |
|------------------------------------|----------|--------------|---------|
| Cardiovascular disease             | 98.03    | 96.43        | 0.206   |
| Ischemic heart disease             | 66.09    | 61.11        | 0.195   |
| Cerebrovascular disease            | 55.53    | 55.95        | 0.915   |
| Ketoacidosis or hyperosmolarity    | 2.46     | 1.19         | 0.389   |
| Retinopathy                        | 29.98    | 28.17        | 0.622   |
| Neuropathy                         | 25.06    | 34.13        | 0.012   |
| Nephropathy                        | 47.17    | 54.76        | 0.058   |
| Myocardial infarction              | 7.62     | 7.14         | 0.822   |
| Ischemic stroke                    | 46.19    | 47.62        | 0.721   |
| Chronic renal failure              | 20.39    | 25.00        | 0.166   |
| Chronic liver disease              | 7.62     | 15.08        | 0.002   |
| Chronic lung disease               | 22.60    | 22.22        | 0.909   |
| Depression                         | 5.90     | 5.56         | 0.855   |
| Charlson's index (mean ± SD)       | 3.91 ± 2.10| 4.38 ± 2.48 | 0.012   |

| Number of different ICD-9 diagnoses (mean ± SD) | 20.46 ± 9.21 | 22.76 ± 10.55 | 0.005 |

### Medication Use (%)

| Medication                     | Northern | Non-northern | P-value |
|--------------------------------|----------|--------------|---------|
| Biguanides                     | 62.41    | 63.89        | 0.702   |
| Sulfonylurea                    | 70.52    | 75.79        | 0.140   |
| Alpha-glucosidase inhibitors   | 18.67    | 21.43        | 0.388   |
| Thiazolidinediones              | 21.62    | 19.84        | 0.585   |
| Glinides                        | 17.94    | 18.25        | 0.918   |
| Fast-acting insulins            | 28.99    | 37.70        | 0.020   |
| Basal insulins                 | 10.81    | 12.70        | 0.461   |
| Aspirin                        | 79.61    | 75.79        | 0.250   |
| Clopidogrel                     | 42.26    | 48.81        | 0.100   |
| Cilostazol                     | 26.54    | 17.46        | 0.007   |
| Warfarin                       | 8.11     | 5.95         | 0.301   |
| ACE inhibitors                  | 39.56    | 46.03        | 0.102   |
| Angiotensin receptor blockers   | 56.02    | 46.03        | 0.013   |
| Alpha-blockers                  | 23.10    | 21.83        | 0.705   |
| Beta-blockers                   | 61.18    | 64.29        | 0.424   |
| Calcium channel blockers        | 74.69    | 79.37        | 0.169   |
| Diuretics                       | 53.56    | 59.92        | 0.110   |
| Statins                         | 53.32    | 51.19        | 0.595   |
| Fibrates                        | 16.46    | 13.49        | 0.304   |

### Resource Utilization (mean ± SD)

| Resource                         | Northern | Non-northern | P-value |
|----------------------------------|----------|--------------|---------|
| A1C measurement                  | 2.25 ± 1.96 | 1.78 ± 1.72 | 0.001   |
| Lipid-related lab test            | 5.99 ± 4.97 | 5.08 ± 5.11 | 0.025   |
| Peripheral artery ultrasound     | 0.04 ± 0.20 | 0.02 ± 0.22 | 0.433   |
| Outpatient visits due to diabetes| 18.78 ± 12.41 | 16.96 ± 11.50 | 0.060 |
| Outpatient visits not due to diabetes | 49.38 ± 28.03 | 52.70 ± 30.40 | 0.153 |
| Emergency department visit       | 1.51 ± 2.68 | 1.44 ± 2.34 | 0.732   |
| Cardiology outpatient visits     | 5.39 ± 8.06 | 6.20 ± 10.03 | 0.275   |
| Cardiovascular surgeon outpatient visits | 2.39 ± 5.12 | 2.48 ± 5.12 | 0.811   |
| Cardiovascular-related physician visits | 20.53 ± 12.39 | 17.86 ± 12.17 | 0.007 |
| Revascularization %              | 9.83     | 12.70        | 0.251   |
| Prior amputation %               | 3.69     | 4.76         | 0.498   |
| Amputation at index hospitalization % | 1.97     | 3.17         | 0.327   |
| Hospitalization due to diabetes  | 0.95 ± 1.37 | 1.07 ± 1.39 | 0.302   |
| Hospitalization not due to diabetes | 1.21 ± 1.55 | 1.37 ± 1.67 | 0.217   |
| Hospitalization due to lower extremity complications | 0.13 ± 0.45 | 0.14 ± 0.42 | 0.805   |

Continued...
The primary outcome of this study was lower extremity amputation, defined by health insurance procedure claims from the inpatient dataset. Lower limb amputation was further stratified by site (i.e., thigh, leg, ankle, and foot). The secondary outcome was a composite endpoint of lower limb amputation, revascularization, or hospitalization for medical treatment including prostaglandin E1, anti-coagulant, or thrombolytic therapy.

Covariate Ascertainment and Adjustment. Inpatient and outpatient diagnosis files as well as the prescription files during the 12-month period before the index date were used to ascertain patients’ past history (ICD-9-CM codes provided in Supplementary Table 1). The medication of each patient during this period was ascertained (Supplementary Table 3).

Statistical Analysis. The instrumental variable (IV) behaves like a natural randomization if it is highly correlated with treatment, but not related to patient characteristics or other confounding factors, nor directly affecting the outcome of interest \(13,14\). Prior studies suggested that treatment calendar year can be used as an IV, given a higher proportion of patients receiving stent placements over time when other patient characteristics were similar\(^{15}\). Other potential IVs included geographical or regional difference and physician preference as they may also influence their treatment decisions due to they have to pay out-of-pocket for the treatment, but is not related to other confounding factors, then it may be appropriate to use recipients’ income as an IV. In the present study, we used monthly income level as IV difference as measured by hospital location in northern or non-northern parts of Taiwan. We did not use doctors’ preference as an instrument because cardiologists can only perform stenting while bypass surgery can only be performed by cardiovascular surgeons in Taiwan (treatment is almost 100% correlated with doctors’ specialty).

Table 4. Baseline characteristics and clinical outcomes of diabetic patients with lower extremity arterial stenosis receiving peripheral artery stenting by regional difference as measured by hospital location in northern and non-northern Taiwan. *Standardized mean difference using non-northern as the reference. SD: standard deviation.

| Outcome occurrence (%) | Northern (N = 407) | Non-northern (N = 252) | P value |
|-------------------------|-------------------|------------------------|--------|
| Number of hospital days | 11.77 ± 20.89     | 11.39 ± 28.84          | 0.856  |
| Number of cardiovascular-related hospital days | 1.06 ± 1.39      | 1.08 ± 1.41           | 0.811  |

Table 5. Risk differences of amputation, revascularization, or hospitalization for medical treatment comparing diabetic patients receiving peripheral artery stenting (N = 659) vs. bypass surgery (N = 5,652) by instrumental variable analyses*. *Risk differences at 2-year using bypass surgery as the reference. IV: instrumental variable.
We followed the recommendations suggested by Swanson SA et al. in conducting instrumental variable analyses. First, we calculated the odds ratios as the strength of association between the proposed instruments and the treatment. Second, falsification tests were done to examine differences in baseline characteristics and the probability to develop outcomes of interest across the levels of instruments. With a logistic regression model, we estimated the the probability of developing study endpoints using indicators for stent placement, as well as age, sex, treatment year, underlying diseases, concomitant medications, 12 months prior to the index date. Third, because we intended to evaluate the comparative effectiveness of endovascular stenting versus bypass surgery in the subpopulation of “compliers”, the proportion of the study population composed of compliers was estimated. If the above conditions appeared justifiable, we then performed a 2-stage least-squares regression to calculate the marginal IV effect estimate. The first stage predicted the stent placement (treatment) as a linear function of IV and all other observed variables. In the second stage, outcome of interest was regressed on the predicted probability of stent placement (treatment), derived from the first stage, along with covariates that were significantly imbalanced between the comparison groups. The regression coefficient for the predicted probability of stent placement (treatment) can be interpreted as an unbiased estimate for risk difference of peripheral artery stenting relative to bypass surgery. More details about instrumental variables were explained in "The Methods of Instrumental Variables.”

All statistical analyses were performed with SAS 9.2 (SAS Institute, Cary, NC). Two-tailed p values less than 0.05 were regarded as statistically significant.

The Methods of Instrumental Variables. Instrumental variable (IV) analysis has primarily been used in economics and social science research to control for confounding and measurement error. Unlike propensity scores, IV can adjust for both measured and unmeasured confounding effects, and hence, allows for the possibility of making causal inference with observational data. IV is unknown to many researchers, and very few good IVs can be found in real clinical setting. In the published medical literature, geographical or regional difference, physician preference, and treatment calendar year have been used as good IVs in the claims database study to reduce confounding effect by unmeasured important clinical factors that are not amenable by traditional regression or propensity score analysis. 

There are three requirements for a variable to be chosen as a good IV (Supplementary Figure 1) the instrument is associated with the treatment, 2) the instrument does not affect the outcome except through treatment, and 3) the instrument does not share any share any cause with the outcome. A perfect example is the randomization indicator in a randomized controlled trial, which is more familiar to medical research readers. More specifically, 1) randomization itself is associated with the treatment, 2) randomization affects the outcome only through experimental treatment, and 3) randomization will create two comparable groups that were very similar in terms of measured and unmeasured risk factors. In observational study, if a good IV can be identified, then IV analysis can be applied to get an unbiased estimate of treatment effect. However, we cannot “prove” a variable to be a good instrument in non-experimental study design, but can only use subject-matter knowledge and provide some empirical data in support of a variable meeting the above three instrumental conditions. The aim of this study is to compare three potential IVs (treatment calendar time, monthly income level, and regional difference) and to use IV analysis evaluating the benefit of stent versus bypass surgery that is closer to the true effect.

For condition #1, an odds ratio between IV and treatment is calculated to evaluate the strength of association. For condition #2 and #3, we present data that showing the proposed instrument is not associated with measured confounders. More specifically, when study participants were categorized based on calendar year (IV), there was an equal distribution in all potential risk factors for the outcome (amputation, revascularization, or hospitalization for medical treatment) (Table 2), just like the first Table in a randomized controlled trial report to demonstrate comparability between treatment groups. This condition also hold true for monthly income level (Table 3), but not for region (Table 4), suggesting calendar year and monthly income level are more appropriate IVs than regional difference.

In a two-arm randomized placebo-controlled trial example, a patient randomized to the treatment group may actually not receive active treatment and a patient randomized to the placebo group may eventually receive active treatment. The compliers are the subset of the trial participants who comply with treatment assigned, that is, the total numbers of participants receive active treatment in the assigned treatment group plus numbers of participants receive placebo in the assigned placebo group then divided by the total number of study participants. This is an important information as the estimated treatment effect will be influenced by the proportion of compliers in a randomized trial. For example, if the true treatment effect is to reduce the risk by 80%, we can only observe a 40% reduction of the risk in a trial with 50% compliers. In statistical language, there are two kinds of treatment effect that can be evaluated, the average treatment effect in the total population (assuming homogeneity, that is, similar effects for all participants) and the local average treatment effect (LATE) in the subpopulation of compliers (assuming non-homogeneity, that is, not all participants had similar effects). Here, the LATE is a treatment effect in a subset of study population, that is, compliers, for whom would have this effect. In the above example, it is very natural to assume the observed treatment effect applies only to those who comply with the trial protocol. IV analysis requires the fourth assumption that the instrument only affects the treatment in one direction (monotonicity). That is, no one takes the opposite of the assigned treatment (“defiers”). Under monotonicity assumption, the IV estimator is consistent with LATE for the compliers. Similar to a randomized placebo-controlled trial example, in our study, for calendar year as an IV, the proportion of compliers would be the number of patients receiving stenting in 2006–2007 plus the number of patients receiving bypass surgery in 2003–2005 then divided by the total number of patients receiving bypass surgery and stenting in 2003–2007 = 396 + 4301/6311 = 0.74. The proportion of compliers in the analyses using monthly income level and regional difference as IV was 0.45, and 0.58, respectively, also suggesting that using treatment calendar year as an IV was more appropriate.

In order to support our argument that IV analysis is superior to traditional or commonly used propensity score analysis to get effect estimates more close to the truth, we also created a propensity-score matched cohort of
stenot revascularization (n = 433) versus peripheral artery bypass surgery (n = 1,196) for the planned comparison (Supplementary Table 4). A significant decrease in amputation risk was found for patients receiving stent revascularization (adjusted HR: 0.67; 95% CI: 0.48–0.92) (Supplementary Table 5). These results, contradictory to the findings from the randomized BASIL (Bypass Versus Angioplasty in Severe Ischemia of the Leg) trial showing similar amputation-free survival with a bypass-surgery-first and a balloon-angioplasty-first strategy, suggesting that IV analysis may be a more appropriate design in analyzing real world data in examining the effectiveness and safety of stent vascularization.

References
1. Kullo, I. J. & Rooke, T. W. CLINICAL PRACTICE. Peripheral Artery Disease. N Engl J Med 374, 861–871, doi: 10.1056/NEJMc1507631 (2016).
2. Sigvant, B., Lundin, F. & Wahlberg, E. The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease. Eur J Vasc Endovasc Surg 51, 395–403, doi: 10.1016/j.ejvs.2015.10.022 (2016).
3. Chang, T. Y. & Shieh, S. J. Revascularization Surgery: Its Efficacy for Limb Salvage in Diabetic Foot. Ann Plast Surg 76 Suppl 1, S13–S18, doi: 10.1097/SAP.0000000000000696 (2016).
4. Thiruvapiot, T., Kielfhorn, C. E. & Armstrong, E. J. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes 6, 961–969, doi: 10.4239/wjd.v6.i7.961 (2015).
5. Rastan, A. et al. One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions: Subgroup Results of the Prospective, Multicenter DEFINITIVE LE Trial. J Endovasc Ther 22, 839–846, doi: 10.1177/15266537156080610 (2015).
6. Jaff, M. R. The challenge of peripheral arterial disease. Curr Vasc Thorac Clin 16, 239–247, doi: 10.1007/s11710-015-0313-0 (2016).
7. Kallmes, D. F. Peripheral arterial disease: A new challenge for vascular radiologists and interventionalists. AJR Am J Roentgenol 189, 942–947, doi: 10.2214/ajr.07.20195 (2007).
8. Wang, J. Y. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382, 1329–1340, doi: 10.1016/S0140-6736(13)61249-0 (2013).
9. Chang, C. H., Lin, W. J., Wu, L. C. & Lai, M. S. Angiotensin receptor blocker blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 29, 3001–3007, doi: 10.1200/JCO.2011.35.1908 (2011).
10. Stukel, T. A. et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 297, 278–285, doi: 297/3/278 [pii] 10.1001/jama.297.3.278 (2007).
32. Hernan, M. A. & Robins, J. M. Instruments for causal inference: an epidemiologist’s dream? Epidemiology 17, 360–372, doi: 10.1097/01.ede.000022409.00878.37 (2006).
33. Venkitachalam, L. et al. Survival benefit with drug-eluting stents in observational studies: fact or artifact? Circ Cardiovasc Qual Outcomes 4, 587–594, doi: CIRCOUTCOMES.111.960971 [pii] 10.1161/CIRCOUTCOMES.111.960971 (2011).
34. Davies, N. M., Smith, G. D., Windmeijer, F. & Martin, R. M. Issues in the reporting and conduct of instrumental variable studies: a systematic review. Epidemiology 24, 363–369, doi: 10.1097/EDE.0b013e31828abaaf (2013).
35. Davies, N. M., Smith, G. D., Windmeijer, F. & Martin, R. M. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis. Epidemiology 24, 352–362 (2013).
36. McClellan, M., McNeil, B. J. & Newhouse, J. P. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 272, 859–866 (1994).
37. Stukel, T. A. et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 297, 278–285 (2007).
38. Venkitachalam, L. et al. Survival benefit with drug-eluting stents in observational studies: fact or artifact? Circ Cardiovasc Qual Outcomes 4, 587–594 (2011).
39. Wang, P. S. et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353, 2335–2341 (2005).

Acknowledgements
This study was in part supported by Ministry of Science & Technology, Taiwan (MOST 104-2314-B-002-036-MY2 and MOST 104-2221-E-002-131-) and National Taiwan University Hospital Yunlin Branch (NTUHYL104.A001) which did not play any role in the study design, collection, analysis, and interpretation of data, in report writing, or in the decision to submit the paper for publication.

Author Contributions
C.H.C. and J.W.L. initiated the study concept and design. C.H.C. and M.S.L. obtained the data. C.H.C. and J.W.L. analyzed and interpreted the data. C.H.C., J.W.L., and J.H. drafted the manuscript. J.H. and M.S.L. revised the manuscript according to important intellectual content. L.C.W. performed statistical analysis. M.S.L., J.W.L., and J.H. obtained funding. The study was supervised by C.H.C.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Chang, C.-H. et al. Stent revascularization versus bypass surgery for peripheral artery disease in type 2 diabetic patients – an instrumental variable analysis. Sci. Rep. 6, 37177; doi: 10.1038/srep37177 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016